Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as ‘lethal mutagenesis’. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication and prevents viral propagation by fostering error accumulation in a process referred to as ‘error catastrophe’.

中文翻译：

---

Molnupiravir：为灾难编码


Molnupiravir 是一种广谱抗病毒药物，目前正处于治疗 COVID-19 的 2/3 期临床试验中，拟通过一种称为“致死诱变”的机制抑制病毒复制。最近发表的两项研究揭示了 molnupiravir 如何破坏 SARS-CoV-2 基因组复制的保真度并通过在称为“错误灾难”的过程中促进错误积累来阻止病毒传播的生化和结构基础。